Italy
Genenta Science is a biotechnology startup based in Italy, founded in 2014, with a focus on developing a proprietary hematopoietic stem cell therapy for solid tumor cancers. Their flagship product, Temferon™, involves ex-vivo gene transfer into autologous Tie2+ hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly to tumor-infiltrating cells. This innovative approach is currently being evaluated in a phase 1/2a clinical trial for newly diagnosed Glioblastoma Multiforme patients with an unmethylated MGMT gene promoter. The company aims to induce a durable immune response in solid tumors without systemic toxicity, addressing key challenges in immuno-oncology.
Genenta Science's recent milestone includes a Post-IPO Secondary investment at 31 December 2021, with Growth Engine participating as the investor. With its focus on disruptive biotechnology and healthcare solutions, Genenta Science is poised to make significant advancements in cancer treatment, attracting attention from post-IPO investors seeking promising opportunities in the biotech industry.
